Alto Neuroscience (NYSE:ANRO) Price Target Cut to $38.00 by Analysts at Robert W. Baird

Alto Neuroscience (NYSE:ANRO) had its price target decreased by Robert W. Baird from $41.00 to $38.00 in a research note published on Thursday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Several other research firms also recently commented on ANRO. Chardan Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a report on Thursday. Wedbush dropped their price target on shares of Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating on the stock in a research report on Thursday. BTIG Research increased their price target on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Alto Neuroscience in a research report on Thursday. Finally, JonesTrading lowered their price objective on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $35.14.

Alto Neuroscience Price Performance

NYSE:ANRO opened at $21.57 on Thursday. Alto Neuroscience has a 52-week low of $1.60 and a 52-week high of $25.17. The company has a market cap of $689.03 million, a P/E ratio of -9.89 and a beta of 2.01. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.69 and a current ratio of 15.69. The stock’s 50-day simple moving average is $19.18 and its 200 day simple moving average is $14.68.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. As a group, sell-side analysts forecast that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

A number of large investors have recently added to or reduced their stakes in ANRO. Commodore Capital LP bought a new stake in Alto Neuroscience in the 4th quarter valued at $32,453,000. Perceptive Advisors LLC boosted its position in Alto Neuroscience by 1,048.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after purchasing an additional 1,629,027 shares during the period. Vestal Point Capital LP increased its holdings in shares of Alto Neuroscience by 161.6% in the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after purchasing an additional 1,535,000 shares during the last quarter. Vivo Capital LLC acquired a new position in shares of Alto Neuroscience in the fourth quarter valued at $18,433,000. Finally, Ikarian Capital LLC raised its position in shares of Alto Neuroscience by 368.2% in the fourth quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock valued at $9,167,000 after purchasing an additional 405,000 shares during the period.

Trending Headlines about Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Multiple firms reaffirmed buy/outperform views and high upside potential: HC Wainwright kept a “buy” and $50 PT, Chardan reaffirmed “buy” with $30 PT, JonesTrading maintained “buy” after lowering its PT to $44, and Robert W. Baird kept an “outperform” while trimming its PT to $38 — these show analyst conviction in Alto’s pipeline despite the miss. Analyst Notes
• Neutral Sentiment: Alto announced it will shift focus toward ALTO-207 and highlighted other pipeline updates following the ALTO-101 topline release — a strategic pivot that could preserve value if follow-on programs show promise, but it’s a longer-term catalyst. ALTO-207 Pivot
• Negative Sentiment: Topline Phase 2 results: ALTO-101 did not achieve statistical significance on the primary endpoint — the direct clinical failure is the main driver of today’s negative price action. Topline Press Release
• Negative Sentiment: Market coverage and headlines amplified the sell-off — multiple outlets reported the failed schizophrenia study and described sizable share declines in pre-market and trading sessions. Expect elevated volume and volatility as investors reassess timelines and probabilities for the rest of the pipeline. Market Reaction
• Negative Sentiment: Some firms became more cautious: Wedbush cut its PT to $21 and set a “neutral” rating — a signal that at least one analyst group sees limited near-term upside after the trial outcome. Wedbush Note

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.